Hazards, Risks, and Threats of Heart Disease from the Early Stages to Symptomatic Coronary Heart Disease and Cardiac Failure

[1]  D. Steinberg.  Antioxidants in the Prevention of Human Atherosclerosis , 2005 .

[2]  W. Kannel,et al.  Clinical misconceptions dispelled by epidemiological research. , 1995, Circulation.

[3]  G. Levine,et al.  Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. , 1995, The New England journal of medicine.

[4]  R. D'Agostino,et al.  Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. , 1995, The New England journal of medicine.

[5]  P. Wilson,et al.  Risk factors that attenuate the female coronary disease advantage. , 1995, Archives of internal medicine.

[6]  W. Kannel.  Risk Factors for Atherosclerotic Cardiovascular Outcomes in Different Arterial Territories , 1994, Journal of cardiovascular risk.

[7]  D. Levy,et al.  Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. , 1994, Circulation.

[8]  W. Kannel,et al.  Changing epidemiological features of cardiac failure. , 1994, British heart journal.

[9]  P. Wilson,et al.  Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. , 1993, JAMA.

[10]  J. Murabito,et al.  Prognosis After the Onset of Coronary Heart Disease An Investigation of Differences in Outcome Between the Sexes According to Initial Coronary Disease Presentation , 1993, Circulation.

[11]  D. Levy,et al.  Survival After the Onset of Congestive Heart Failure in Framingham Heart Study Subjects , 1993, Circulation.

[12]  D. Ornish.  Can lifestyle changes reverse coronary heart disease? , 1993, World review of nutrition and dietetics.

[13]  W. Kannel.  Potency of vascular risk factors as the basis for antihypertensive therapy. , 1992, European heart journal.

[14]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[15]  W. Willett,et al.  A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. , 1992, JAMA.

[16]  R. Grimm,et al.  The white blood cell count and risk for coronary heart disease. , 1992, American heart journal.

[17]  D. Steinberg,et al.  Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of a National Heart, Lung, and Blood Institute Workshop: September 5-6, 1991, Bethesda, Maryland. , 1992, Circulation.

[18]  E. Ernst.  Fibrinogen: the plot thickens. , 1992, Journal of clinical epidemiology.

[19]  K. Anderson,et al.  Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. , 1992, Journal of the American College of Cardiology.

[20]  K. Anderson,et al.  White blood cell count and cardiovascular disease. Insights from the Framingham Study. , 1992, JAMA.

[21]  M. Goldstein.  Serum Cholesterol as a Prognostic Factor after Myocardial Infarction , 1992, Annals of Internal Medicine.

[22]  W. Kannel,et al.  Long- and short-term risk of sudden coronary death. , 1992, Circulation.

[23]  Kannel Wb.  Epidemiology of cardiovascular disease in the elderly: an assessment of risk factors. , 1992, Cardiovascular clinics.

[24]  W. Kannel.  Epidemiology of cardiovascular disease in the elderly: an assessment of risk factors. , 1992, Cardiovascular clinics.

[25]  P. Wilson,et al.  Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. , 1991, Annals of internal medicine.

[26]  J. Huttunen,et al.  Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. , 1991, Atherosclerosis.

[27]  R. DeFronzo,et al.  Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease , 1991, Diabetes Care.

[28]  K. Anderson,et al.  An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.

[29]  M J Malloy,et al.  Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. , 1990, JAMA.

[30]  L. Wilhelmsen,et al.  Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. , 1990, BMJ.

[31]  R. D'Agostino,et al.  Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. , 1990, American heart journal.

[32]  K. Gould,et al.  Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial , 1990, The Lancet.

[33]  D. Spodick,et al.  The incidence and prognosis of unrecognized myocardial infarction. , 1990, Archives of internal medicine.

[34]  G. Utermann,et al.  The mysteries of lipoprotein(a). , 1989, Science.

[35]  W. Kannel.  Epidemiological aspects of heart failure. , 1989, Cardiology clinics.

[36]  W C Willett,et al.  Low-density lipoprotein subclass patterns and risk of myocardial infarction. , 1988, JAMA.

[37]  W. Kannel,et al.  Cardiac failure and sudden death in the Framingham Study. , 1988, American heart journal.

[38]  F. Lindgärde,et al.  Higher total plasma homocysteine in vitamin B12 deficiency than in heterozygosity for homocystinuria due to cystathionine beta-synthase deficiency. , 1988, Metabolism: clinical and experimental.

[39]  V. Nguyen.  Fibrinogen and risk of cardiovascular disease: Kannel WB, Wolf PA, Castelli WP, et al JAMA 258: 1183–1186 Sep 1987 , 1988 .

[40]  R. D'Agostino,et al.  Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.

[41]  M. Norusis,et al.  Homocysteinemia due to folate deficiency. , 1987, Metabolism: clinical and experimental.

[42]  W. Kannel,et al.  Unrecognized myocardial infarction and hypertension: the Framingham Study. , 1985, American heart journal.

[43]  W. Kannel,et al.  Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. , 1984, The New England journal of medicine.

[44]  M. Fisher,et al.  Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. , 1984, Circulation.

[45]  N. Benevenga,et al.  Accumulation of homocyst(e)ine in vitamin B-6 deficiency: a model for the study of cystathionine beta-synthase deficiency. , 1982, The Journal of nutrition.

[46]  D L McGee,et al.  Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study , 1979, Diabetes Care.

[47]  W. Kannel,et al.  Menopause and Coronary Heart Disease: The Framingham Study , 1978 .

[48]  W. Kannel,et al.  Menopause and risk of cardiovascular disease: the Framingham study. , 1977, Annals of internal medicine.

[49]  M. Oliver.  The menopause and coronary heart disease , 1976 .